affiliation not provided to SSRN
BRAF mutation, Colorectal cancer, Biomarker, Sex, MEK inhibitor, binimetinib
BRAF mutation, colorectal cancer, Biomarker, sex, MEK inhibitor, binimetinib
Breast cancer, radiotherapy-induced side-effects, non-coding RNA polymorphisms, predictive models